An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients with a slow-growing type of lymphoma — study results that are likely to secure the treatment’s approval and help it rival a custom-made CAR-T therapy.
The study enrolled 90 patients, all of whom were given intravenous infusions of the Roche drug, called mosunetuzumab. Complete remissions were reported in 54 patients, or 60%, meaning their disease was undetectable. The overall response rate was 80% with median duration of response lasting nearly 23 months. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/2021/12/12/roche-two-armed-antibody-posts-strong-tumor-responses-in-lymphoma-study-rivaling-car-t-therapy/
